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ORIGINAL ARTICLE
Brain endothelial miR-146a negatively modulates T-cell
adhesion through repressing multiple targets to inhibit NF-κB
activation
Dongsheng Wu1, Camilla Cerutti1, Miguel A Lopez-Ramirez1,2, Gareth Pryce3, Josh King-Robson3, Julie E Simpson4,
Susanne MA van der Pol5, Mark C Hirst1, Helga E de Vries5, Basil Sharrack6, David Baker3, David K Male1, Gregory J Michael3 and
Ignacio A Romero1
Pro-inflammatory cytokine-induced activation of nuclear factor, NF-κB has an important role in leukocyte adhesion to, and
subsequent migration across, brain endothelial cells (BECs), which is crucial for the development of neuroinflammatory disorders
such as multiple sclerosis (MS). In contrast, microRNA-146a (miR-146a) has emerged as anti-inflammatory molecule by inhibiting NF-
κB activity in various cell types, but its effect in BECs during neuroinflammation remains to be evaluated. Here, we show that
miR-146a was upregulated in microvessels of MS-active lesions and the spinal cord of mice with experimental autoimmune
encephalomyelitis. In vitro, TNFα and IFNγ treatment of human cerebral microvascular endothelial cells (hCMEC/D3) led to
upregulation of miR-146a. Brain endothelial overexpression of miR-146a diminished, whereas knockdown of miR-146a augmented
cytokine-stimulated adhesion of T cells to hCMEC/D3 cells, nuclear translocation of NF-κB, and expression of adhesion molecules in
hCMEC/D3 cells. Furthermore, brain endothelial miR-146a modulates NF-κB activity upon cytokine activation through targeting two
novel signaling transducers, RhoA and nuclear factor of activated T cells 5, as well as molecules previously identified, IL-1 receptor-
associated kinase 1, and TNF receptor-associated factor 6. We propose brain endothelial miR-146a as an endogenous NF-κB
inhibitor in BECs associated with decreased leukocyte adhesion during neuroinflammation.
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INTRODUCTION
In neuroinflammation such as multiple sclerosis (MS), the blood–
brain barrier (BBB) becomes compromised with intensive migration
of leukocytes into the central nervous system (CNS), contributing
to disease pathogenesis.1 To migrate into the CNS, leukocytes
follow a finely regulated sequence of events starting from
tethering and rolling along the vessel, then firmly adhering to
and migrating out of the vasculature. Firm adhesion is triggered
by chemokines and mediated by interactions between integrins
on leukocytes and adhesion molecules on brain endothelial cells
(BECs).2
Overwhelming evidence highlights that the nuclear factor, NF-
κB, drives transcription of cell adhesion molecules, chemokines,
and pro-inflammatory cytokines.3 The NF-κB complex consists of a
family of dimeric transcription factors comprising RelA (p65), RelB,
c-Rel, p50, and p52. The classic pathway involves p50/p65 hetero-
dimers complexed to IκB in unstimulated cells. Upon stimulation,
IKKβ mediates the phosphorylation-induced ubiquitination of IκB,
which frees p50/p65 to translocate to the nucleus to initiate gene
transcription.3 NF-κB also coordinates with other signaling path-
ways, such as RhoA and transforming growth factor-β to modulate
the inflammatory response.4,5 NF-κB has been proposed as a
therapeutic target for the treatment of MS,3 thereby highlighting
endogenous inhibitors of NF-κB as potential novel therapies.
MicroRNAs (miRNAs) are endogenous noncoding RNAs ~ 22
nucleotides long that pair to the 3′-untranslated region of
messenger RNAs and incorporate them into RNA-induced silen-
cing complexes to repress gene expression. Accumulating
evidence implicates certain miRNAs in the pathogenesis of MS
and experimental autoimmune encephalomyelitis (EAE): miR-155
contributes to the pathogenesis of EAE by modulating T-cell
differentiation and promoting endothelial barrier dysfunction,6,7
whereas brain endothelial miR-125a-5p tightens BBB and prevents
leukocyte migration during inflammation.8
NF-κB not only initiates the transcription of protein-coding
genes but also drives the expression of miRNA precursors, which
act as feedback modulators of NF-κB.9 Among them, miR-146a is
an NF-κB-dependent gene and downregulates NF-κB activities
by repressing two signal transducers in human monocytes: TNF
receptor-associated factor 6 (TRAF6) and IL-1 receptor-associated
kinase 1 (IRAK1).10 Several studies suggest miR-146a as a mole-
cular brake on inflammation, myeloid cell proliferation, and
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oncogenic transformation.11 The anti-inflammatory role of miR-146a
has been demonstrated in several cell types including mono-
cytes,10 T cells,12 astrocytes,13 human umbilical vein endothelial
cells (HUVECs),14 and human BECs. 15 However, its function in BECs
remains to be elucidated. Here we show that miR-146a is
upregulated in cytokine-activated BECs and decreases leukocyte
adhesion by inhibiting NF-κB through repressing not only TRAF6
and IRAK1 but also RhoA and nuclear factor of activated T cells 5
(NFAT5).
MATERIALS AND METHODS
All animal procedures conform to the Animals (Scientific Procedures) Act
1986 of the UK government and the Animal Research: Reporting of In Vivo
Experiments guidelines, and are approved after ethical review processes by
Queen Mary University of London and the Open University Animal Care
and Use Committees.
Human brain tissue and primary human T cells
Human brain tissues of MS patients (four females and two males, 34 to 88
years old) and control patients (six males, 35 to 84 years old) without
neurologic diseases were obtained from The UK Multiple Sclerosis Tissue
Bank (Imperial College London, London, UK) according to local human
ethical guidelines (For clinical information and pathological characteriza-
tion of MS and control patients please see ref. 7). Primary human T cells
were obtained from buffy coats (Sanquin, Amersterdam, The Netherlands)
of healthy volunteers (after informed consent, following the Netherlands
human ethical guidelines) through Ficoll gradient centrifugation, followed
by negative selection of the primary T cells using MACS magnetic cell
sorting kit (Miltenyi Biotec, Bergisch Gladbach, Germany) according to the
manufacturer’s instructions.16
Cell lines
The immortalized human brain microvascular endothelial cell line (hCMEC/D3)
was cultured on collagen-coated culture flasks or multi-well plates in
EGM-2MV medium supplemented with 2.5% fetal bovine serum and
growth factors (Lonza, Slough Wokingham, UK).7 The Jurkat T lymphocyte
cell line was a kind gift from Dr V Male (Cambridge University, Cambridge,
UK) and cultured in suspension in RPMI1640 (Life Technologies, Paisley,
UK) with 10% fetal bovine serum.
Induction of experimental autoimmune encephalomyelitis
Adult female and male (10 to 12 weeks) Biozzi ABH mice were purchased
from Harlan UK (Bicester, UK). Animals were grouped randomly and
maintained on a 12 hours: 12 hours light: dark cycle and received food and
water ad libitum. EAE was induced in Biozzi ABH mice with freeze-dried
mouse spinal cord homogenate emulsified with complete Freunds
adjuvant supplemented as previously described.7 Animals were monitored
daily to assess the development of relapsing–remitting paralysis and
scored as follows: 0 = normal; 1 = limp tail; 2 = impaired righting reflex;
3 = hind-limb paresis; 4 = complete hind-limb paralysis and 5=moribund/
death. Two (2/44) animals scored 5 and were excluded from the
experiments. The EAE status was based on paralytic clinical disease and
weight loss/gain as follows: onset of signs: clinical score 1, with weight loss
sampled on day 15 post induction; acute-phase paralysis (APP): clinical
score 3.5 to 4, with weight loss by day 17; recovery: clinical score 3.5 to 1,
with weight gain by day 20; remission one: clinical score 0.5, with weight
gain by day 28 after induction. Data collection and analysis were
performed by researchers masked to the experimental groups.
Laser capture microdissection and isolation of microvessels
Laser capture microdissection of MS brain microvessels was used to collect
enriched brain endothelium RNA as previously described.7 Approximately
200 blood vessels were isolated from each case using PixCell II laser
capture microdissection system (Arcturus BioScience, Mountain View, CA,
USA) and laser capture microdissection-caps (Applied Biosystems, War-
rington, UK). For mouse spinal cords, microvessels were isolated as
previously described.7 Briefly, EAE or normal ABH mice were perfused with
0.5% bovine serum albumin in Hank’s balanced solution to rinse out the
blood, then the spinal cords were flushed out of vertebral columns. For
each replicate, spinal cords of three mice in the same group were pooled
together to get sufficient amount of RNA and counted as one (total
animals used, nine mice per group), digested with collagenase and dispase
(1mg/mL) at 37 °C for 1 hour, and, finally, homogenized and centrifuged
through 25% bovine serum albumin. The pellet of microvessels underwent
a second digestion for 30 minutes and microvessel fragments were
purified and separated from single contaminating cells by passing through
a 70-μm-size mesh filter. Enrichment of endothelium within the micro-
vessel fraction was examined by quantitative RT-PCR for endothelial
markers (claudin-5, PECAM-1), astrocyte marker GFAP, and leukocyte marker
CD45, as previously described.7,8
RNA extraction and quantitative reverse transcriptase-polymerase
chain reaction
Total RNA of hCMEC/D3 cells and microvessels isolated from human
brain or mouse spinal cords were extracted using TRIzol reagent (Life
Technologies). For each sample, 10 ng of total RNA was used for reverse
transcription. Expression of miR-146a and U6B small nuclear RNA were
measured with TaqMan MicroRNA Assays Kit (Life Technologies). U6B was
used as internal control. QuantiTect SYBR Green PCR kit (Qiagen,
Manchester, UK) was used to determine the relative levels of two NF-κB
target genes vascular cell adhesion molecule-1 (VCAM1) and chemokine
C-C motif ligand 2 (CCL2). β-Actin was used as internal control. The primers
were 5′-CATTTGACAGGCTGGAGATAGA-3′ and 5′-CTCTTGGTTTCCAGGGAC
TT-3′ for VCAM1 (GenBank Accession Number M73255.1), 5′-GGCTGAGACT
AACCCAGAAAC3′ and 5′GAATGAAGGTGGCTGCTATGA-3′ for CCL2 (GenBank
Accession Number NM_002982.3), and 5′-GGACCTGACTGACTACCTCAT-3′ and
5′-CGTAGCACAGCTTCTCCTTAAT-3′ for β-actin (NM_001101.3). The method
of 2−ΔΔCT was used for analysis of the data.7
Immunohistochemistry and in situ hybridization
Cryostat sections of lumbar spinal cords from 4% paraformaldehyde-
perfused EAE mice at day 10 after EAE induction (D10, n=5), in the initial
acute phase paralysis of EAE with a clinical score of 4 (APP, n=5), and
control mice without EAE induction (n=5) underwent immunohistochem-
ical staining for endothelial specific marker with rat anti-PECAM-1
monoclonal antibody (1:50, BD Biosciences, Oxford, UK) followed with a
secondary goat anti-rat IgG Alexa Fluor 555 (1:400, Life Technologies) and
nuclei staining with Hoechst 33342 (Life Technologies). Images were
captured using a Leica DMRB fluorescence microscope with a Hamamatsu
C4742-95 digital camera and HiPic software (Herrsching, Germany). Then
in situ hybridization of miR-146a was performed using double-digoxigenin
labeled miRCURY LNA probe (Exiqon, Vedbaek, Denmark) after proteinase
K digestion following the manufacturer’s protocol with modification.7
Briefly slides were treated with 2 μg/mL proteinase K (Roche, West Sussex,
UK) at 37 °C for 10 minutes, fixed for 5 minutes in 4% paraformaldehyde
and dehydrated in 70% ethanol. Sections were prehybridized in hybri-
dization buffer consisting of 50% formamide, 5 × saline sodium citrate and
100 μg/mL sheared salmon sperm DNA at 52 °C for 30 minutes. Double-
digoxigenin-labeled miRCURY LNA probe miR-46a oligonucleotide at a
concentration of 5 nM was hybridized with the sections overnight at 52 °C.
A similarly labeled LNA scrambled oligonucleotide was used as a negative
control. Sections were washed through a series of 5-minute washes in 5 ×
to 0.2 × saline sodium citrate at 55 °C, incubated overnight with sheep
anti-digoxigenin antibody conjugated with alkaline phosphatase (1:1,000,
Roche, West Sussex, UK), then incubated in NBT/BCIP (Roche, West Sussex,
UK) and levamisole (Vector Labs, Peterborough, UK) at 30 °C, then washed
in KTBST (50mM Tris HCl pH 7.5, 150 mM NaCl, 20 mM KCl, 0.5% Tween-20)
for 1 to 6 hours to reduce the background signal. Sections were re-stained
in Hoechst 33342. NBT/BCIP precipitate was photographed using a Nikon
Eclipse 80i fluorescence microscope with an MBF CX9000 digital camera
and PictureFrame software.
Cell transfection
A total of 30 nM of Pre-miR-146a were transfected into hCMEC/D3 cells
using siPORT Amine transfection agent (Life Technologies), whereas 60 nM
of miR-146a inhibitor (Anti-miR-146a) and siGENOME SMARTpool siRNAs
for human RelA, IRAK1, TRAF6, STAT1, ROCK1, RhoA, and NFAT5 (Thermo-
Fisher Scientific, Epsom, UK) were transfected into cells using Lipofecta-
mine 2000 (Life Technologies). Non-targeting scrambled Pre-miR, Anti-miR,
or siRNA control pools was used as negative controls, respectively. Cy3
Dye-Labeled Pre-miR or Anti-miR Negative Control #1 (Life Technologies),
siGLO Red Transfection Indicator (ThermoFisher Scientific) was used for
analyzing transfection efficiency.
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Leukocyte adhesion assay under shear flow
Jurkat T-cell and primary human T-cell adhesion assay was performed as
previously described with modification.17,18 Briefly, hCMEC/D3 cells were
grown on collagen-coated ibidi μ-Slide VI0.4 six-channel slides (Ibidi GmbH,
Martinsried, Germany) until confluence. Primary human T cells were
activated by 48-hour stimulation with IL-2 (10 ng/mL) and phytohemag-
glutinin (1 μg/mL). Then Jurkat T cells or activated primary human T cells
(2 × 106/mL) were labeled with 5 mM CMFDA (5-chloromethylfluorescein
diacetate, Life Technologies) and were allowed to flow through the
channel and accumulate for 5 minutes at low shear stress (0.5 dyn/cm2).
Shear stress (τ) was calculated according to τ= 176.1 ηФ (η= 0.01,
Ф= volumetric flow rate). Images were recorded at one frame
per second with an inverted time-lapse fluorescence microscope (Olympus
IX70, Tokyo, Japan) by using Image Pro Plus software (Media Cybernetics,
Bethesda, MD, USA). Then, the culture medium was pulled through the
channel at a physiologic shear stress (1.5 dyn/cm2) for 1 minute to wash
away the leukocytes, which were not firmly adhered to the endothelium.
Under physiologic shear stress, images were taken randomly from at least
five fields per channel (640 × 480 μm2/field). Firmly adherent Jurkat T cells
were then counted using Image Pro Plus software.
Immunocytochemistry
hCMEC/D3 cells grown on glass coverslips coated with collagen were fixed
with 4% paraformaldehyde and permeabilized with methanol and acetone
at − 20 °C for 10 and 1 minute, respectively, then incubated with rabbit
anti-NF-κB p65 (1:100, Cell Signaling Technology, Danvers, MA, USA)
followed by goat anti-rabbit IgG Alexa Fluor 488 (1:400, Life Technologies).
Cell nuclei were stained using Dapi Fluoromount-G (SouthernBiotech,
Birmingham, Alabama, USA). Images were captured with a Zeiss Axiophot
fluorescent microscope. Number of cells with nuclear staining of NF-κB p65
was expressed as percentage of total cell numbers demonstrated by DAPI
(4',6-diamidino-2-phenylindole). Experiments were performed at three
time points (0.5, 6, and 24 hours after cytokine stimulation), each
performed in three experimental samples with duplicates each counting
over 100 cells in three to six randomly selected fields.
Western blot analysis
Cell lysates were separated by 10% (20% for RhoA) sodium dodecyl
sulfate–polyacrylamide gel electrophoresis gels and transferred onto
nitrocellulose membranes (Amersham, Buckinghamshire, UK), probed with
rabbit anti-IRAK1 or TRAF6 or RelA or ROCK1 (1:1,000, Cell Signaling
Technology), or rabbit anti-NFAT5 (1:1,000, Thermo Scientific, Northumber-
land, UK), or STAT1 (1:500, Santa Cruz Biotechnology, Dallas, TX, USA), or
mouse anti-RhoA (1:100, Cytoskeleton, Denver, CO, USA), or mouse anti-
VCAM1 (1:100, R&D Systems Europe, Abingdon, UK), or mouse anti-β-actin
(1:5,000 Sigma, Dorset, UK), followed with horseradish peroxidise-
conjugated goat anti-rabbit IgG (1:3,000; Life Technologies) or anti-
mouse IgG (1:3,000 for RhoA, 1:14,000 for β-actin; Pierce Biotechnology,
Cheshire, UK). Immunoblots were then developed by enhanced chemilu-
minescence detection (ECL, Amersham, Buckinghamshire, UK).
Lentiviral transduction of 3′-untranslated region reporter vectors
and luciferase assay
The luciferase reporter lentiviral vector constructs containing the puro-
mycin resistance gene and the luciferase gene from the firefly Photinus
pyralis with the 3′-untranslated region (UTR) of RhoA (1061 bases), NFAT5
(5′-2100 bases) (Applied Biological Materials, British Columbia, VIC, Canada)
were used to transduce hCMEC/D3 cells with a multiplicity of infection of 3.
Mutated 3′-UTR versions of putative target genes were obtained by
replacing the corresponding miR-146a target sites with AAGA using site-
directed mutagenesis. Twenty-four hours after transduction, cells were
transfected with Pre-miR-146a or scrambled Pre-miR. Seventy-two hours
later, luciferase activity was quantified using the Steady-Glo Luciferase
assay system (Promega, Madison, WI, USA) and luminescence was deter-
mined using the FLUOstar OPTIMA plate reader (BMG LABTECH GmbH,
Ortenberg, Germany).
Statistical analysis
All values are presented as means ± s.e.m. Student's paired t-test was used
for human MS samples, Jurkat T-cell or primary human T-cell adhesion
assay. Student's t-test was used for 3′-UTR luciferase assay. For other
experiments, one-way ANOVA (analysis of variance) was used for single
time point experiments and post hoc with Bonferroni correction for
multiple comparisons on SPSS software. Two-way ANOVA was used for
multiple time point experiments. Statistical significance was considered if
Po0.05.
RESULTS
Neuroinflammation induces upregulation of central nervous
system endothelial miR-146a
To elucidate the role of endothelial miR-146a in BBB dysfunction
in neuroinflammatory diseases such as MS, we first characterized
its expression in human brain microvessels of MS lesions, isolated
by laser capture microdissection. In comparison with normal-
appearing white matter, cerebral microvascular miR-146a increased
~ 1.5-fold in the active lesions of MS (Figure 1A). We then
examined the temporal expression pattern of miR-146a in the
spinal cord microvasculature of EAE mice, isolated by enzyme
digestion. The enrichment of endothelium was confirmed, as
previously reported by our lab,7 by high gene expression levels of
endothelial specific markers (claudin-5, PECAM-1) and by low
expression of astrocyte marker GFAP and leukocyte marker CD45,
compared with the reference gene β-actin. Mice at initial acute-
phase paralysis of EAE (EAE-APP) with a clinical score of 4 showed
an 8-fold increase of miR-146a in the microvessels of the spinal
cord compared with normal control animals (Figure 1B). The level
of miR-146a returned back to basal levels during EAE-remission
stage. We further demonstrated, via in situ hybridization, the
abundant expression of miR-146a in the lumbar spinal cord of
EAE-APP mice, and its co-localization with the endothelial maker
PECAM-1 (Figure 1C). In non-EAE control mice or in EAE mice at
day 10 (D10) after immunization (before onset of signs), endo-
thelial expression of miR-146a was not detectable or very low,
respectively (Figure 1C). In cultured human brain endothelial
hCMEC/D3 cells, an in vitro BBB model, tumor necrosis factor alpha
(TNFα) and interferon gamma (IFNγ) (1 ng/mL each) upregulated
the expression of miR-146a at 6 and 24 hours by 4-fold of that
in nonstimulated control cells and this increase was still
largely maintained (~3-fold) by 48 hours post cytokine stimulus
(Figure 1D). These results indicate that inflammatory mediators
induce a tightly spatial and temporal expression of miR-146a,
thereby suggesting an important role at brain endothelium in the
affected areas during neuroinflammation.
Brain endothelial miR-146a partially prevents cytokine-stimulated
leukocyte adhesion
As miR-146a levels increase in the brain endothelium during
neuroinflammation, we then further investigated the role of brain
endothelial miR-146a in BBB dysfunction, particularly on leukocyte
adhesion to brain endothelium in vitro. We first manipulated the
levels of miR-146a in hCMEC/D3 cells grown on six-channel slides
by transfection with Pre-miR-146a or Anti-miR-146a to increase or
decrease the expression of miR-146a, respectively (Supplementary
Figures 1A and 1B). For all experiments, over 90% transfection
efficiency was consistently achieved (Supplementary Figure 1C). At
day 1 post-transfection, cells were treated with 1 ng/mL TNFα and
IFNγ for 24 hours and exposed to CMFDA-labeled Jurkat T cells for
5 minutes at 0.5 dyn/cm2 to mimic the blood flow in the micro-
vasculature (Supplementary Videos A–C). Jurkat T cells adhered to
endothelial cells were analyzed after flushing away non-adhered
cells at 1.5 dyn/cm2. We observed that ectopic expression of
miR-146a or inhibition of basal miR-146a by Anti-miR-146a did
not affect Jurkat T-cell adhesion to nonstimulated hCMEC/D3
monolayers (Figures 2A and 2B). In contrast, stimulation of
endothelium with 1 ng/mL TNFα and IFNγ for 24 hours
induced increase in Jurkat T-cell adhesion by around 10-fold
when compared with non-treated cells (Figures 2A and 2B).
Furthermore, overexpression of miR-146a in brain endothelium
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partially prevented Jurkat T-cell adhesion to cytokine-activated
hCMEC/D3 cells by ~ 21% (Figure 2A; Supplementary Videos B and
C). Preventing cytokine-induced increase in miR-146a resulted in
augmented Jurkat T-cell adhesion by ~ 39% (Figure 2B). Similarly,
overexpression of miR-146a in brain endothelium partially
prevented primary human T-cell adhesion to cytokine-activated
hCMEC/D3 cells by ~ 17% (Figure 2C). Altogether, these results
indicate TNFα and IFNγ induced increase of brain endothelial
miR-146a that negatively modulates Jurkat T-cell adhesion.
miR-146a modulates brain endothelial NF-κB activation
The critical role of NF-κB in leukocyte adhesion to and migration
across endothelium is well established, so we next investigated
whether miR-146a modulates NF- κB activity in brain endothelium.
Following immunostaining of NF-κB p65, our results show that
1 ng/mL of TNFα and IFNγ induced nuclear translocation of NF-κB
p65 in hCMEC/D3 cells, which peaked at 0.5 hours and was largely
sustained from 6 to 24 hours (Figures 3A–3C). Overexpression of
miR-146a decreased cytokine-induced NF-κB p65 nuclear translo-
cation at all three time points, by 8%, 20%, and 10% at 0.5, 6, and
24 hours, respectively, compared with their scrambled controls
(Figures 3A and 3B, ). By contrast, miR-146a knockdown enhanced
cytokine-induced NF-κB p65 nuclear translocation by 3%, 7%, and
15% over that of scrambled control at 0.5, 6, and 24 hours,
respectively (Figure 3C). In line with a previous report on the role
of NF-κB on monocyte adhesion to umbilical vein endothelium,18
we confirmed that knockdown of RelA (NF-κB p65) via small
interference RNA (Figure 3D) decreased Jurkat T-cell adhesion to
human cytokine-activated brain endothelium by 67% in compar-
ison with its scrambled control (Figure 3E). These results suggest
that cytokine-induced miR-146a upregulation in brain endothe-
lium negatively regulated upstream activators of NF-κB signaling.
miR-146a targets IRAK1 and TRAF6 in brain endothelium
As microRNAs regulate cellular processes and cell signaling
through silencing target molecules, using different online
databases (microRNA.org, MiRanda, and TargetScan), we identified
four potential target genes for miR-146a with known NF-κB
regulatory activity, STAT1, ROCK1, RhoA, and NFAT5, in addition to
the well-known miR-146a targets, IRAK1 and TRAF6. Indeed,
these two genes have already been validated as targets of
miR-146a in several cell types including monocytes, T cells and
astrocytes,10,12,13 and are involved in the regulation of NF-κB
activity and expression of NF-κB target genes such as VCAM1 and
TNFα.13,14 We transfected hCMEC/D3 cells with Pre-miR-146a or
scrambled control, then treated cells with 1 ng/mL TNFα and IFNγ
for 0.5, 6, and 24 hours. In the control conditions, cytokines
increased IRAK1 (by 1.25-fold over untreated control) at 0.5 hours,
with levels decreasing considerably (by 25% to 40%) at later
time points (Figures 4A and 4B). In contrast, TRAF6 expression
Figure 1. miR-146a is increased in CNS microvessels and cultured brain endothelium during inflammation. (A) Quantitative RT-PCR analysis of
miR-146a in brain endothelial cells isolated by laser capture microdissection from normal-appearing white matter (NAWM) and MS-active
lesions (n= 6). Data show the relative abundance of miR-146a normalized to the small nuclear RNA U6B. P= 0.039 by paired Student’s t-test. (B)
Expression of miR-146a in mouse spinal cord microvessels isolated by enzyme digestion was analyzed using quantitative RT-PCR. Samples of
three mice were pooled as one, nine mice were used for each group. Normal, control Biozzi ABH mice; APP, EAE mice at acute-phase paralysis
with a clinical grade score of 4 at day 17; remission, EAE mice at the first remission stage showing a clinical score of 0.5 and gain of body
weight at day 28. Data represent mean± s.e.m., n= 3, ***Po0.001 compared with normal or remission via analysis of variance (ANOVA). (C)
Representative photomicrographs show, by in situ hybridization in combination of immunohistochemistry, the expression of miR-146 in
PECAM-1 positive spinal cord microvessels of a mouse at day 10 after EAE induction (D10, upper panels) or an EAE-APP mice at day 17 (lower
panels), respectively. Left panels show expression of miR-146a (red arrows). Middle panels show immunostaining of endothelium-specific
marker PECAM-1 (white arrows). Right panels show merged images to demonstrate co-localization of miR-146a and PECAM-1 (red arrows).
Hoechst 33342 labels nuclei (light blue). Scale bar, 25 μm. (D) Brain endothelial cell line hCMEC/D3 cells were confluent and left unstimulated
or stimulated with 1 ng/mL of TNFα and IFNγ for 0.5, 6, 24, or 48 hours. Expression of miR-146a was analyzed with quantitative RT-PCR and
normalized to the small nuclear RNA U6B. Values of nonstimulated cells were set as 1. Data represent mean± s.e.m., n= 3, *Po0.05, **Po0.01
compared with untreated control via ANOVA. CNS, central nervous system; EAE-APP, experimental autoimmune encephalomyelitis-acute-
phase paralysis; IFNγ, interferon gamma;miR, microRNA; MS, multiple sclerosis; RT-PCR, reverse transcriptase-polymerase chain reaction; TNFα,
tumor necrosis factor alpha.
Brain endothelial miR-146a and T-cell adhesion
D Wu et al
4
Journal of Cerebral Blood Flow & Metabolism (2014), 1 – 12 © 2014 ISCBFM
levels were increased at all the three time points by cytokine
treatment (1.1 to 1.4-fold of untreated control; Figures 4A and 4C,
). We show that ectopic expression of miR-146a suppressed levels
of IRAK1 and TRAF6 (Figures 4A–4C), in either untreated or
cytokine-treated hCMEC/D3 cells at all the three time points by
western blot analysis. Moreover, knockdown of the expression of
IRAK1 or TRAF6, alone or in combination, via small interference
RNAs (siIRAK1, siTRAF6; Supplementary Figures 3A and 3B),
significantly decreased cytokine-induced leukocyte adhesion
(Figures 4D–4F), and this effect was associated with decreased
nuclear translocation of NF-κB (Figure 4G). We did not observe
synergistic or additive effects when knockdown of TRAF6 and
IRAK1 was conducted simultaneously by small interference RNAs.
Two additional potential miR-146a targets, STAT1, and ROCK1,
have been, respectively, validated in prostate carcinoma cells19
and Treg cells.
20 However, in brain endothelium, miR-146a sup-
pressed neither STAT1 nor ROCK1 protein expression (Supple-
mentary Figure 2).
miR-146a targets NFAT5 and RhoA in brain endothelium
We further investigated two novel potential targets for miR-146a
in brain endothelium that have not been previously validated:
RhoA and NFAT5. We transfected hCMEC/D3 cells with Pre-
miR-146a, then treated them with 1 ng/mL TNFα and IFNγ for 0.5,
6, and 24 hours. In controls, cytokines increased NFAT5 (~20%
more than untreated control) from 0.5 to 6 hours, after which
levels decreased slightly (Figures 5A and 5B, ). In contrast, RhoA
levels decreased by 20% at 6 hours, then increased by 20% at
24 hours (Figures 5A and 5C, ). We show that ectopic expression of
miR-146a suppressed levels of both NFAT5 and RhoA (Figures 5A–
5C), in either untreated or cytokine-treated hCMEC/D3 cells at all
the three time points by western blot analysis. Moreover,
knockdown of NFAT5 or RhoA expression using small interference
RNAs (siNFAT5, siRhoA; Supplementary Figure 3C), significantly
decreased leukocyte adhesion to cytokine-activated brain endo-
thelium by 33% or 37%, respectively (Figures 5D and 5E, ). siNFAT5
downregulated nuclear translocation of NF-κB by15%, 14%, and
11% at 0.5, 6, and 24 hours, respectively, compared with their
scrambled controls, while siRhoA decreased nuclear translocation
of NF-κB by 7% at all the three time points (Figure 5F). Further-
more, in hCMEC/D3 cells transduced with lentiviral luciferase
reporter vectors containing the 3’-UTR of RhoA or NFAT5, over-
expression of miR-146a significantly decreased luciferase activity
by 50% and 30%, respectively, in comparison with scrambled
controls, but no decrease was detected in cells transduced with
lentiviral luciferase reporter vector containing mutated 3’-UTR
versions of either RhoA or NFAT5 (Figure 5G). These results
demonstrated that miR-146a have a key role in modulating NF-κB
activity by repressing multiple cytokine-effectors.
miR-146a inhibits expression of NF-κB target genes in brain
endothelium
As miR-146a modulates NF-κB activation by repressing multiple
targets, we then examined its effect on the mRNA and protein
expression of two NF-κB target genes: VCAM1 and CCL2, which
play key roles in leukocyte adhesion to endothelium. In cytokine-
treated hCMEC/D3 cells, VCAM1 and CCL2 mRNA levels increased
by 70- and 50-fold over that of untreated cells, respectively,
whereas overexpression of miR-146a by transfection with Pre-
miR-146a decreased the cytokine-induced levels of VCAM1 and
CCL2 by 50% (Figure 6A). In contrast, decreased expression of
miR-146a by transfection with Anti-miR-146a increased the level of
VCAM1 mRNA in cytokine-activated hCMEC/D3 cells (Figure 6B).
CCL2 mRNA levels were also increased by transfection with Anti-
miR-146a but did not reach statistical significance. Consistently,
knockdown of NFAT5 and RhoA by siRNA decreased the
transcription levels of VCAM1 and CCL2 by 50% in cytokine-
stimulated cells (Figure 6D), whereas siIRAK1 and siTRAF6 did not
markedly alter the levels of VCAM1 and CCL2 mRNA (Figure 6C).
We further examined the protein levels of VCAM1 in hCMEC/D3
cells transfected with Pre-miR-146a or with siRNA for its target
molecules. Cytokines increased the level of VCAM1 protein,
whereas ectopic expression of miR-146a significantly decreased
cytokine-induced levels of VCAM1 protein (Figure 6E). In addition,
siRNA-mediated knockdown of IRAK1, TRAF6, RhoA, and NFAT5
significantly decreased VCAM1 protein levels in cytokine-activated
cells (Figures 6F–6H), which is in line with that downregulated by
siRelA (Figure 6I).
Taken together, these results indicate that cytokine-induced
increase in brain endothelial miR-146a negatively regulates NF-κB
Figure 2. miR-146a modulates Jurkat T-cell adhesion to cytokine-
stimulated hCMEC/D3 cells. hCMEC/D3 cells in six-channel slides
were transfected with Pre-miR-146a or scrambled Pre-miR, and left
untreated or treated with 1 ng/mL TNFα and IFNγ for 24 hours.
hCMEC/D3 cells were then exposed to CMFDA-labeled Jurkat T cells
for 5 minutes at 0.5 dyn/cm2. (A) Quantitative analysis of the effects
of Pre-miR-146a on Jurkat T-cell adhesion. (B) Quantitative analysis
of the effects of Anti-miR-146a on Jurkat T-cell adhesion. (C)
Quantitative analysis of the effects of Pre-miR-146a on primary
human T-cell adhesion. Data represent mean± s.e.m., n= 4 for Jurkat
T-cell adhesion assay, n= 3 for primary human T-cell adhesion assay,
experiments for each group at each condition were performed in
duplicates. *Po0.05, **Po0.01, ***Po0.001 via Student's paired t-
test. IFNγ, interferon gamma; miR, microRNA; TNFα, tumor necrosis
factor alpha.
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activation via repression of multiple targets upstream of NF-κB signal-
ing, highlighting its anti-inflammatory role in brain endothelium.
DISCUSSION
miR-146a has been demonstrated as a NF-κB inhibitor in several
cell types other than brain endothelium. In this study, we provide
evidence that brain endothelial miR-146a represses multiple
targets: NFAT5, RhoA, IRAK1, and TRAF6, to inhibit NF-κB activity,
and subsequently negatively modulate leukocyte adhesion
(Figure 7).
In vivo, we have shown that miR-146a is significantly
upregulated in isolated microvessels of MS-active lesion and of
spinal cords of mice during EAE-APP. In the spinal cords of EAE
mice, we further confirmed the expression of miR-146a in
endothelium by in situ hybridization combined with immunohis-
tochemistry. The expression of miR-146a starts to appear before
Figure 3. miR-146a in hCMEC/D3 cells negatively modulates nuclear NF-κB translocation. (A) Photomicrographs show NF-κB p65 (RelA)
staining in scrambled or Pre-miR-146a transfected hCMEC/D3 cells untreated or treated with 1 ng/mL TNFα and IFNγ for 0.5, 6, and 24 hours.
Scale bar, 100 μm. (B) Effects of Pre-miR-146a on nuclear translocation of NF-κB p65 in hCMEC/D3 cells. Note ectopic expression of miR-146a
suppressed nuclear translocation of NF-κB p65 at all three time points. Two-way analysis of variance (ANOVA) tests of all the time points after
cytokine treatment demonstrate significant difference between the Scrambled and Pre-miR-146a groups (Po0.001). One-way ANOVA was
used to compare the difference at each time point between the two groups. Data represent mean± s.e.m., n= 3, *Po0.05, **Po0.01. (C)
Effects of Anti-miR-146a on nuclear translocation of NF-κB p65 in hCMEC/D3 cells. Note that knockdown of miR-146a increased nuclear
translocation of NF-κB p65 at all the three time points. Two-way ANOVA tests of all the time points after cytokine treatment demonstrate
significant difference between the Scrambled and Anti-miR-146a groups (Po0.001). One-way ANOVA was used to compare the difference at
each time point between the two groups. Data represent mean± s.e.m., n= 3, *Po0.05. (D) RelA small interference (siRelA) or small
interference control (siControl) was transfected into hCMEC/D3 cells in 12-well plates, 48 hours later, cells were left untreated or treated with
1 ng/mL TNFα and IFNγ for 0.5, 6, and 24 hours, subject to western blot for RelA. Note that siRelA suppressed expression of RelA in either
untreated or cytokine-stimulated cells at all the three time points. siRNA− , siControl; siRNA+, siRelA. (E) Decreased expression of RelA
prevented Jurkat T-cell adhesion to cytokine-stimulated hCMEC/D3 cells. Data represent mean± s.e.m., n= 4, *Po0.05, **Po0.01 via
Student's paired t-test. IFNγ, interferon gamma; miR, microRNA; TNFα, tumor necrosis factor alpha.
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the onset of signs, reaches high levels during EAE-APP when pro-
inflammatory cytokines are extensively produced1–3 and max-
imum cell infiltration is occurring around the vasculature, and
draws back to baseline at remission when BBB dysfunction is
restored and with minimal cell infiltration.7 This observation is in
line with the increased expression of miR-146a detected in active
MS lesions and in cytokine-treated astrocytes.21 We also demon-
strate that miR-146a is upregulated in cytokine-activated cultured
BECs, where NF-κB activation occurs earlier than miR-146a
upregulation. It is possible that miR-146a is transcribed upon
onset of inflammation by NF-κB and levels increase during acute
stage of inflammatory conditions to resolve neuroinflammation
Figure 4. miR-146a targets IRAK1 and TRAF6 to modulate NF-κB activation and Jurkat T-cell adhesion. (A) Western blot analysis show that
overexpression of miR-146a via transfection with Pre-miR-146a repressed the expression of IRAK1 and TRAF6 in hCMEC/D3 cells either
unstimulated or cytokine (1 ng/mLTNFα/IFNγ)-stimulated for 0.5, 6, and 24 hours. (B, C) Quantification of protein levels of IRAK1 and TRAF6 via
ImageJ. Data represent mean± s.e.m., n= 3, *Po0.05, **Po0.01, ***Po0.001 via analysis of variance (ANOVA) with post hoc comparison and
Bonferroni correction. (D) Knockdown of the expression of IRAK1 via small interference RNA for IRAK1 (siIRAK1) decreased Jurkat T-cell
adhesion to cytokine-stimulated hCMEC/D3 cells. (E) Knockdown of the expression of TRAF6 via siTRAF6 downregulated Jurkat T-cell adhesion
to cytokine-stimulated hCMEC/D3 cells. (F) Knockdown of the expression of IRAK1 and TRAF6 simultaneously decreased Jurkat T-cell adhesion
to cytokine-stimulated hCMEC/D3 cells. Data represent mean± s.e.m., n= 3 to 4, *Po0.05, **Po0.05, ***Po0.001 via ANOVA. (G) Statistical
analysis of the effects of siIRAK1 and siTRAF6 on nuclear translocation of NF-κB. Two-way ANOVA tests of all the time points after cytokine
treatment demonstrate significant difference between the siControl and siIRAK1 or siTRAF6 or siIRAK1+siTRAF6 groups (Po0.01). One-way
ANOVA was used to compare the difference with siControl at each time point. Data represent mean± s.e.m., n= 3, *Po0.05, **Po0.01. IFNγ,
interferon gamma; IRAK, IL-1 receptor-associated kinase 1; miR, microRNA; TNFα, tumor necrosis factor alpha; TRAF, TNF receptor-associated
factor.
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Figure 5. miR-146a targets NFAT5 and RhoA to modulate NF-κB activation and Jurkat T-cell adhesion. (A) Western blot analysis show that
overexpression of miR-146a via transfection with Pre-miR-146a repressed the expression of NFAT5 and RhoA in hCMEC/D3 cells either
untreated or treated with cytokines for 0.5, 6, and 24 hours. (B, C) Quantification of protein levels of NFAT5 and RhoA via ImageJ. Data
represent mean± s.e.m., n= 3, *Po0.05, **Po0.01, ***Po0.001 via analysis of variance (ANOVA) with post hoc comparison and Bonferroni
correction. (D) siNFAT5 decreased Jurkat T-cell adhesion to cytokine-stimulated hCMEC/D3 cells. (E) siRhoA downregulated Jurkat T-cell
adhesion to cytokine-stimulated hCMEC/D3 cells. Data represent mean± s.e.m., n= 3 to 4, *Po0.05, **Po0.01, ***Po0.001 via Student's
paired t-test. (F) Statistical analysis of the effects of siNFAT5 and siRhoA on nuclear translocation of NF-κB. Two-way ANOVA tests of all the time
points after cytokine treatment demonstrate significant difference between the siControl and siNFAT5 or siRhoA groups (Po0.001). One-way
ANOVA was used to compare the difference with siControl at each time point. Data represent mean± s.e.m., n= 3, **Po0.01, ***Po0.001. (G)
3’-UTR luciferase assay demonstrated that miR-146a overexpression led to decreased luciferase activity in hCMEC/D3 cells transduced with
lentiviral luciferase vector containing the 3’-UTR of RhoA or NFAT5 but not with the corresponding mutated 3’-UTR versions. Text box
demonstrates a sequence alignment of human miR-146a (hsa-miR-146a) and two target sites in the 3’-UTR of RhoA and one target site in the
3’-UTR of NFAT5. Mutated 3’-UTR for RhoA or NFAT5 (mut-RhoA, mut-NFAT5) was performed by replacing the corresponding miR-146a target
sites with four nucleotides: AAGA. Data represent mean± s.e.m., n= 3, *Po0.05 via Student's t-test. miR, microRNA; 3’-UTR, 3’-untranslated
region.
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(Figure 7). It is thus reasonable to predict that miR-146a may act as
an anti-inflammatory microRNA in astrocytes and brain endothe-
lial cells as they form a functional neurovascular unit to maintain
the integrity of BBB.22
NF-κB has been shown to play a central role in several
autoimmune diseases such as MS.3 The NF-κB pathway fulfils
diverse roles in development, maturation, activation and pro-
liferation of lymphocytes, and in regulating pro-inflammatory and
anti-inflammatory function of dendritic cells and macrophages.3
Brain endothelial transcripts regulated by NF-κB may include not
only miR-146a11 but also nitric oxide synthases, pro-inflammatory
cytokines, chemokines and cell adhesion molecules.3 In cultured
brain,23 umbilical vein,18 or retina24 endothelial cells, inhibition of
NF-κB activity reduces TNFα-induced permeability and/or leuko-
cyte migration. In vivo, reagents used to block NF-κB activity can
reduce the incidence of disease and clinical score of EAE.25 Here,
we show that endothelial miR-146a diminishes both Jurkat T-cell
and primary T-cell adhesion to BECs, an effect that is associated
with a decrease in NF-κB nuclear translocation. Similar effects on
leukocyte adhesion to endothelium have been observed with NF-
κB inhibitors such as MG-132, adenoviral IκB,18,23 and small
interference for RelA (Figure 3D). The effect of miR-146a on NF-κB
nuclear translocation was relatively small at the very early time
point. This may result from the fine tuning properties of miRNAs7
and the kinetics of NF-κB nuclear translocation that peaks at early
time points and then resolves gradually (Figure 3A). Furthermore,
the relative large effect of miR-146a at later time points may result
from additive effects of NF-κB induced negative feedback
regulators such as Bcl3 and IκB.3 Nevertheless, the general effect
of endothelial miR-146a on leukocyte adhesion to BECs through
inactivating NF-κB is evident. Even though MS is regarded as a T
lymphocyte-dependent chronic inflammatory disease, other cells
like B cells, dendritic cells, macrophages, and CNS-resident glia
also contribute to the pathogenesis of disease.3 The effects of
endothelial expression of miR-146a on other cell types including
various subsets of T cells remain to be explored.
It has been demonstrated that miR-146a negatively modulates
NF-κB through downregulating TRAF6 and IRAK1.10–13 In BECs, we
also demonstrated that miR-146a repressed translation of TRAF6
and IRAK1 in response to TNFα and IFNγ. Knockdown of TRAF6
and IRAK1 either individually or simultaneously show similar
effects as miR-146a on Jurkat T-cell adhesion and nuclear
translocation of NF-κB, although simultaneous knockdown of
both proteins together did not result in synergistic effects. TRAF6
and IRAK1 have been mainly associated with IL-1β signal
transduction leading to NF-κB activation,10–13 but several reports
demonstrate a role for these two signaling molecules in TNFα-
induced NF-κB activation.26–28 In addition, an endogenous IL-1
inhibitor, IL1 receptor antagonist (IL-1RA), blocked IL-1β- but not
TNFα/INFγ-induced NF-κB activation and Jurkat T-cell adhesion to
BECs (Supplementary Figure 4), indicating that TNFα-induced IL-1
expression was not involved in the miR-146a-mediated TRAF6
and/or IRAK1 inhibition on NF-κB activity. This effect is, however,
limited, suggesting the involvement of other NF-κB modulators
targeted by miR-146a that are specific for TNFα and IFNγ.
However, levels of another two known miR-146a targets, ROCK1
(ref. 19) and STAT1 (ref. 20), were not affected by miR-146a
overexpression, suggesting tissue-specific actions of miRNAs.
We also identified two other novel miR-146a targets known to
modulate NF-κB activity, NFAT5, and RhoA. NFAT5 together with
NFAT1–4 belong to the Rel family, sharing 15% to 17% identity
with p50 in the Rel homology region.29 Most reports on NFAT5
refer to its transcriptional activity in the context of hypertonicity.29
However, its role in inflammation is only beginning to emerge,
with evidence that pro-inflammatory cytokines TNFα, IL-1, IL-6,
IL-18, and chemokines, such as CXCL8, CCL2, and CCL5 are
transcriptional targets of NFAT5 in various cell types and under
various inflammatory stimuli.29,30 Furthermore, there appears to
be cross-talk between NFAT5 and NF-κB30 or Wnt/β-catenin,31
where the latter is important for BBB development. Accumulating
evidence suggests the onset of local or systemic hyperosmolality
during the course of various inflammatory disorders, such as
diabetic microvascular lesions and inflammatory bowel disease.
Recently, it has been reported that a high-salt diet leads to a more
severe EAE clinical outcome through an effect relying on p38-
MAPK and NFAT5-dependent Th17 development.32 We provide
further evidence that NFAT5 is involved in the activation of
cerebral endothelium by cytokines, particularly concerning
regulation of NF-κB activation and T-cell adhesion.
RhoA, Cdc42, and Rac1 are members of the Rho family of
small GTPases. Endothelial Rho has been shown to have a crucial
role in leukocyte migration across BECs either by modulating
the cytoskeleton to embrace leukocytes by promoting docking
structures33 or by acting as an intercellular adhesion molecule-1
(ICAM1) signal transducer.34 In other endothelium (mostly
HUVECs), RhoA has been shown to modulate expression of
cytokines, adhesion molecules, and chemokines via Rho/ROCK/
(actin cytoskeleton)/NF-κB signaling cascade.4 Rho family mem-
bers and their exchange factors Dbl, Ost, and Vav potently activate
NF-κB, though other transcription factors such as the activating
protein-1 (AP-1) family member c-Jun and may also coordinately
act together to modulate NF-κB activities. Our results demonstrat-
ing a link between miR-146a and RhoA are in agreement with the
role of RhoA in NF-κB activation and leukocyte adhesion to
endothelium.
We have also examined the levels of adhesion molecules
downregulated by miR-146a (Figure 6), because of the well-
documented observation that NF-κB initiates adhesion molecule
expression and chemokine production in multiple cell types
including brain endothelial cells.3 It seems a reasonable assump-
tion therefore, that cerebral endothelial miR-146a may regulate
signal transducers for NF-κB activation posttranscriptionally,
thereby leading to decreased expression of NF-κB transcriptional
targets. Indeed, our results are in line with those obtained in
HUVECs, where manipulating levels of miR-146 had a significant
indirect effects on transcription of ICAM1, VCAM1, E-selectin, CCL2,
whereas these effects are not only because of targeting of NF-κB
activation but also other signaling molecules such as mitogen-
activated protein kinase/early growth response pathway and AP-1
signaling.15 Unexpectedly, we also observed that siIRAK1 and/or
siTRAF6 decreased VCAM1 protein levels without affecting its
corresponding mRNA levels. It is possible that the role of these
two signaling proteins in the inflammatory activation of brain
endothelial cells induced by cytokines is a complex process and
that, in addition to their role in NF-κB-mediated transcriptional
activation, IRAK1, and TRAF6 may regulate inflammatory mole-
cules such as VCAM1 at the posttranslational level. As an example,
IL-1 activates a translational control mechanism that modulates
expression of a group of genes,35 including IL-6, via IRAK1. Alter-
natively, combination of pro-inflammatory cytokines increases the
half-life of VCAM1 mRNA,36 and TRAF6 and IRAK1 actively regulate
the ubiquitin-proteasome system.37 It is thus conceivable that
VCAM1 protein turnover is affected by ablation of IRAK1 and/or
TRAF6 in the absence of apparent changes of VCAM1 mRNA levels
by a mechanism that remains to be determined.
In summary, we have delineated further the underlying mecha-
nisms through which miR-146a affects T-cell adhesion to human
brain endothelium by identifying two novel targets NFAT5 and
RhoA, and we have demonstrated the role of IRAK1 and TRAF6,
two signaling molecules usually associated with IL-1R and Toll-like
receptor responses, in brain endothelial activation by TNFα and
IFNγ, we have characterized the temporal and spatial expression
of miR-146a in CNS endothelium in MS-active lesions, EAE model,
and cultured brain endothelium. As the complex signaling
networks appear to control inflammation progression,28,38 it is
unlikely that rational therapeutic strategies should focus on
Brain endothelial miR-146a and T-cell adhesion
D Wu et al
9
© 2014 ISCBFM Journal of Cerebral Blood Flow & Metabolism (2014), 1 – 12
modulating the activity of one signaling molecule. Indeed, the
emerging role of miRNAs in directly regulating complex signaling
networks involved in inflammation, such as cell adhesion
molecules39,40 by targeting the expression of several genes makes
them suitable therapeutic targets for neuroinflammatory
disorders. The limited increase of miR-146a in MS brain
endothelium further stresses the necessity to increase miR-146a
through therapeutic manipulation to counteract inflammatory
responses, thereby potentially preventing the progression of MS
pathogenesis.
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